Abstract
Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1316-1317 |
| Number of pages | 2 |
| Journal | Journal of Association of Physicians of India |
| Volume | 50 |
| Issue number | 10 |
| State | Published - Oct 2002 |
ASJC Scopus subject areas
- Medicine(all)